Ignite Creation Date:
2024-05-06 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 12:54 PM
Study NCT ID:
NCT03685331
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-10-06
First Post:
2018-09-18
Brief Title:
HOPE Olaparib Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated HR HER2-metastatic Breast Cancer
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Abramson Cancer Center at Penn Medicine
Organization Data
Organization:
Abramson Cancer Center at Penn Medicine
Class:
OTHER
Study ID:
UPCC 21118
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None